Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04537299 · ClinicalTrials.gov registry record · Phase 2
COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT04537299: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT04537299 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04537299, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether Fisetin, a senolytic drug, can assist in preventing an increase in the disease's progression and alleviate complications of coronavirus due to an excessive inflammatory reaction.
Interventions
- DRUG Placebo
- DRUG Fisetin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-04-29 |
| Est. Completion | 2024-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04537299
The ClinicalTrials.gov registry entry for NCT04537299 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04537299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04537299 about?
NCT04537299 is a clinical study titled "COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes". The purpose of this study is to test whether Fisetin, a senolytic drug, can assist in preventing an increase in the disease's progression and alleviate complications of coronavirus due to an excessive inflammatory reaction.
What is the current status of trial NCT04537299?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2022-04-29. Estimated completion is 2024-11-30.
What interventions are being tested in trial NCT04537299?
The interventions under investigation include: Placebo (DRUG), Fisetin (DRUG).
Who is sponsoring clinical trial NCT04537299?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.